Purespring Therapeutics has secured $105 million in Series B funding to advance its gene therapies for kidney diseases, particularly targeting IgA nephropathy (IgAN). The funding, led by Sofinnova Partners, will support a Phase 1/2 study of its lead candidate, utilizing adeno-associated viruses to deliver treatments aimed at the podocytes, which are linked to many renal diseases. The company plans to present its IgAN data at the upcoming American Society of Nephrology’s Kidney Week meeting.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.